Dominant intraprostatic cancer confirmed by direct MRI-guided biopsy

Concordance with histopathological findings

Nicholas P. Meermeier, Kevin Turner, Bryan Foster, Csanád Várallyay, Jen-Jane Liu, Fergus Coakley

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Purpose: To investigate the concordance between dominant intraprostatic cancer seen on endorectal multiparametric MRI and confirmed by MRI-targeted biopsy with histopathological findings at radical prostatectomy, since existing literature has emphasized the miss rather than the concordance rate of MRI. Materials and methods: We retrospectively identified 20 patients who underwent radical prostatectomy after a dominant intraprostatic cancer focus was identified at endorectal multiparametric MRI and confirmed by MRI-targeted biopsy. Concordance was determined by comparing the location and Gleason grade group of dominant tumor at MRI with the location and Gleason grade group determined at histopathological review. Results: Mean patient age was 65 years (range, 48 to 76) and median serum prostatic specific antigen level was 9.4 ng/mL (range, 4.6 to 58.0). In all 20 patients, the location of dominant tumor based on MRI and targeted biopsy corresponded with the dominant tumor location at histopathology. In 9 patients, Gleason grade group was the same at targeted biopsy and final histopathology. In 9 patients, final Gleason grade group was higher and in two patients it was lower. Conclusion: Our preliminary results suggest dominant tumor as determined by endorectal multiparametric MRI and confirmed by a positive MRI-targeted biopsy has high concordance with histopathological findings at radical prostatectomy for location, and reasonable concordance for Gleason grade group.

Original languageEnglish (US)
Pages (from-to)273-278
Number of pages6
JournalClinical Imaging
Volume51
DOIs
StatePublished - Sep 1 2018

Fingerprint

Biopsy
Prostatectomy
Neoplasms
Antigens
Serum

Keywords

  • MRI
  • MRI targeted biopsy
  • Prostate cancer

ASJC Scopus subject areas

  • Radiology Nuclear Medicine and imaging

Cite this

Dominant intraprostatic cancer confirmed by direct MRI-guided biopsy : Concordance with histopathological findings. / Meermeier, Nicholas P.; Turner, Kevin; Foster, Bryan; Várallyay, Csanád; Liu, Jen-Jane; Coakley, Fergus.

In: Clinical Imaging, Vol. 51, 01.09.2018, p. 273-278.

Research output: Contribution to journalArticle

@article{01e8fc0045b044579104e98b41482a63,
title = "Dominant intraprostatic cancer confirmed by direct MRI-guided biopsy: Concordance with histopathological findings",
abstract = "Purpose: To investigate the concordance between dominant intraprostatic cancer seen on endorectal multiparametric MRI and confirmed by MRI-targeted biopsy with histopathological findings at radical prostatectomy, since existing literature has emphasized the miss rather than the concordance rate of MRI. Materials and methods: We retrospectively identified 20 patients who underwent radical prostatectomy after a dominant intraprostatic cancer focus was identified at endorectal multiparametric MRI and confirmed by MRI-targeted biopsy. Concordance was determined by comparing the location and Gleason grade group of dominant tumor at MRI with the location and Gleason grade group determined at histopathological review. Results: Mean patient age was 65 years (range, 48 to 76) and median serum prostatic specific antigen level was 9.4 ng/mL (range, 4.6 to 58.0). In all 20 patients, the location of dominant tumor based on MRI and targeted biopsy corresponded with the dominant tumor location at histopathology. In 9 patients, Gleason grade group was the same at targeted biopsy and final histopathology. In 9 patients, final Gleason grade group was higher and in two patients it was lower. Conclusion: Our preliminary results suggest dominant tumor as determined by endorectal multiparametric MRI and confirmed by a positive MRI-targeted biopsy has high concordance with histopathological findings at radical prostatectomy for location, and reasonable concordance for Gleason grade group.",
keywords = "MRI, MRI targeted biopsy, Prostate cancer",
author = "Meermeier, {Nicholas P.} and Kevin Turner and Bryan Foster and Csan{\'a}d V{\'a}rallyay and Jen-Jane Liu and Fergus Coakley",
year = "2018",
month = "9",
day = "1",
doi = "10.1016/j.clinimag.2018.06.008",
language = "English (US)",
volume = "51",
pages = "273--278",
journal = "Clinical Imaging",
issn = "0899-7071",
publisher = "Elsevier Inc.",

}

TY - JOUR

T1 - Dominant intraprostatic cancer confirmed by direct MRI-guided biopsy

T2 - Concordance with histopathological findings

AU - Meermeier, Nicholas P.

AU - Turner, Kevin

AU - Foster, Bryan

AU - Várallyay, Csanád

AU - Liu, Jen-Jane

AU - Coakley, Fergus

PY - 2018/9/1

Y1 - 2018/9/1

N2 - Purpose: To investigate the concordance between dominant intraprostatic cancer seen on endorectal multiparametric MRI and confirmed by MRI-targeted biopsy with histopathological findings at radical prostatectomy, since existing literature has emphasized the miss rather than the concordance rate of MRI. Materials and methods: We retrospectively identified 20 patients who underwent radical prostatectomy after a dominant intraprostatic cancer focus was identified at endorectal multiparametric MRI and confirmed by MRI-targeted biopsy. Concordance was determined by comparing the location and Gleason grade group of dominant tumor at MRI with the location and Gleason grade group determined at histopathological review. Results: Mean patient age was 65 years (range, 48 to 76) and median serum prostatic specific antigen level was 9.4 ng/mL (range, 4.6 to 58.0). In all 20 patients, the location of dominant tumor based on MRI and targeted biopsy corresponded with the dominant tumor location at histopathology. In 9 patients, Gleason grade group was the same at targeted biopsy and final histopathology. In 9 patients, final Gleason grade group was higher and in two patients it was lower. Conclusion: Our preliminary results suggest dominant tumor as determined by endorectal multiparametric MRI and confirmed by a positive MRI-targeted biopsy has high concordance with histopathological findings at radical prostatectomy for location, and reasonable concordance for Gleason grade group.

AB - Purpose: To investigate the concordance between dominant intraprostatic cancer seen on endorectal multiparametric MRI and confirmed by MRI-targeted biopsy with histopathological findings at radical prostatectomy, since existing literature has emphasized the miss rather than the concordance rate of MRI. Materials and methods: We retrospectively identified 20 patients who underwent radical prostatectomy after a dominant intraprostatic cancer focus was identified at endorectal multiparametric MRI and confirmed by MRI-targeted biopsy. Concordance was determined by comparing the location and Gleason grade group of dominant tumor at MRI with the location and Gleason grade group determined at histopathological review. Results: Mean patient age was 65 years (range, 48 to 76) and median serum prostatic specific antigen level was 9.4 ng/mL (range, 4.6 to 58.0). In all 20 patients, the location of dominant tumor based on MRI and targeted biopsy corresponded with the dominant tumor location at histopathology. In 9 patients, Gleason grade group was the same at targeted biopsy and final histopathology. In 9 patients, final Gleason grade group was higher and in two patients it was lower. Conclusion: Our preliminary results suggest dominant tumor as determined by endorectal multiparametric MRI and confirmed by a positive MRI-targeted biopsy has high concordance with histopathological findings at radical prostatectomy for location, and reasonable concordance for Gleason grade group.

KW - MRI

KW - MRI targeted biopsy

KW - Prostate cancer

UR - http://www.scopus.com/inward/record.url?scp=85048308205&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85048308205&partnerID=8YFLogxK

U2 - 10.1016/j.clinimag.2018.06.008

DO - 10.1016/j.clinimag.2018.06.008

M3 - Article

VL - 51

SP - 273

EP - 278

JO - Clinical Imaging

JF - Clinical Imaging

SN - 0899-7071

ER -